Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NT219
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : University of Colorado, Denver
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NT219 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : NT219
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : University of Colorado, Denver
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CM-24,Paclitaxel,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : CM-24,Paclitaxel,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Immunorizon
Deal Size : $101.0 million
Deal Type : Acquisition
Details : The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $3.5 million
February 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Immunorizon
Deal Size : $101.0 million
Deal Type : Acquisition
Lead Product(s) : NT219,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Menashe Bar-Eli
Deal Size : Undisclosed
Deal Type : Collaboration
Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
Details : This collaboration will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 26, 2021
Lead Product(s) : NT219,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Menashe Bar-Eli
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
